Table 2.

In vivo tumorigenicity of CD44⁺CD117⁺ ovarian tumor cells

Tumor/cell type	Cell doses and tumor formation and latency (d)							Serial transplantation rate
Tumor/cell type	100	500	1,000	5,000	10,000	100,000	500,000	Serial transplantation rate
T1 xenograft
CD44⁺CD117⁺	2/2 (77, 93)	—	2/2 (65, 78)	—	2/2 (62, 70)	—	—	3/3
CD44⁻CD117⁻	—	0/2	0/2	—	0/2	—	1/2 (132)	—
T2 xenograft
CD44⁺CD117⁺	2/2 (52, 72)	—	2/2 (59, 80)	—	2/2 (43, 65)	—	—	3/3
CD44⁻CD117⁻	—	0/2	0/2	—	0/2	—	2/2 (91, 103)	—
T3 primary
CD44⁺CD117⁺	2/2 (63, 75)	—	2/2 (50, 74)	2/2 (65, 89)	—	—	—	3/3
CD44⁻CD117⁻	0/2	—	0/2	—	0/2	0/2	—	—
T4 spheroids
CD44⁺CD117⁺	1/2 (55)	—	2/2 (42, 60)	—	2/2 (60, 69)	—	—	N/A
CD44⁻CD117⁻	—	—	—	0/2	0/2	0/2	0/2	—
T5 spheroids
CD44⁺CD117⁺	2/2 (50, 65)	—	1/2 (52)	—	2/2 (45, 62)	—	—	N/A
CD44⁻CD117⁻	—	—	—	0/2	0/2	0/2	0/2	—

NOTE: All in vivo tumorigenicity experiments were done in the left flank of athymic mice by s.c. injection.

Abbreviation: N/A, not applicable.